Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase LATS1

CHEMBL6167 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:21:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6167
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase LATS1 as ChEMBL target CHEMBL6167, mapped to UniProt O95835. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase LATS1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6167
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O95835
Serine/threonine-protein kinase LATS1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase LATS1 matters

As of 2026-09-13

Serine/threonine-protein kinase LATS1 is reviewed as Serine/threonine-protein kinase LATS1 (UniProt O95835); the current evidence base includes 7 approved drugs, 784 compounds, and 172 assays, with lead potency reaching pChEMBL 9.2.

Protein context
Serine/threonine-protein kinase LATS1

Serine/threonine-protein kinase LATS1 Sequence length is 1130 aa.

Review this target as Serine/threonine-protein kinase LATS1, mapped to UniProt O95835. Sequence length is 1130 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt O95835 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 784 compounds, and 172 assays for this target. The dominant activity type is IC50. CHEMBL4439972 is the current potency anchor at pChEMBL 9.2.

Use CHEMBL4439972 as the tractability anchor when discussing potency (pChEMBL 9.2).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 9.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase LATS1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O95835, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

784
Total Compounds
172
Total Assays
7
Approved Drugs
IC50: 593.0, KD: 365.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4439972
 9.2 IC50 —
No preferred name
CHEMBL4447153
 9.1 IC50 —
No preferred name
CHEMBL4525078
 9.1 IC50 —
No preferred name
CHEMBL4463018
 9.1 IC50 —
No preferred name
CHEMBL4463415
 9.1 IC50 —

Approved Drugs

Structure Compound First Approval
GILTERITINIB
CHEMBL3301622
 2018
NINTEDANIB
CHEMBL502835
 2014
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:21:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6167